Propranolol inhibits infantile hemangioma by regulating the miR-424/vascular endothelial growth factor-A (VEGFA) axis

Background Infantile hemangioma (IHA) is the most common tumor in infancy. We aimed to explore the effect of propranolol on the expression of microRNA (miR)-424 in IHA tissues and XPTS-1 cells, as well as its molecular mechanism of inhibiting XPTS-1 cell activity. Methods Tumor tissues and peritumoral tissue were collected from 13 IHA patients in Lishui Municipal Central Hospital. The level of miR-424 were detected using real-time quantitative reverse transcription polymerase chain reaction (RT-PCR). Cell counting kit-8 (CCK-8) was used to measure XPTS-1 cell viability. Flow cytometry and transwell were used to detect the apoptosis level and invasion ability of XPTS-1 cells. Western blot was used to measure the protein level of vascular endothelial growth factor-A (VEGFA). The luciferase reporter gene assay detected the targeting relationship between miR-424 and VEGFA. Results Compared with normal tissues and human umbilical vein endothelial cells, the expression level of miR-424 in IHA tissues and XPTS-1 cells was significantly reduced (P<0.05). As the concentration of propranolol increased, XPTS-1 cell viability gradually decreased (P<0.05), and the expression level of VEGFA decreased (P<0.05). The expression of miR-424 increased with the time of propranolol treatment (P<0.05). Compared with the control group, treatment with an miR-424 inhibitor resulted in a significant increase in XPTS-1 cell viability and invasion ability (P<0.05), and a decrease in apoptosis (P<0.05). However, both propranolol and miR-424 inhibitor treatment resulted in a partial decrease in XPTS-1 cell viability (P<0.05), and a partial increase in the level of apoptosis (P<0.05). MiR-424 directly targeted VEGFA; the overexpression of miR-424 resulted in a decrease in the VEGFA protein level (P<0.05), while inhibition of miR-424 resulted in an increase in the VEGFA protein level (P<0.05). Compared with the propranolol group, the XPTS-1 cell viability and invasion ability in the propranolol + VEGFA-si group were significantly decreased (P<0.05), while the level of apoptosis increased (P<0.05). Meanwhile, simultaneous miR-424 inhibitor treatment resulted in no difference in cell viability and apoptosis levels compared with the propranolol group, and the invasion ability was partially restored (P<0.05). Conclusions Propranolol affects the malignant biological behavior of IHA cells by regulating the miR-424/VEGFA axis.

[1]  Yubin Gong,et al.  LncRNA-MALAT1 promotes tumorogenesis of infantile hemangioma by competitively binding miR-424 to stimulate MEKK3/NF-κB pathway. , 2019, Life sciences.

[2]  Biao Gao,et al.  Long non-coding RNA 00152 slicing represses the growth and aggressiveness of hemangioma cell by modulating miR-139-5p. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  Zhi-Yao He,et al.  Progress in the treatment of infantile hemangioma. , 2019, Annals of translational medicine.

[4]  Dongdong Jiang,et al.  Propranolol suppresses infantile hemangioma cell proliferation and promotes apoptosis by upregulating miR-125b expression , 2019, Anti-cancer drugs.

[5]  T. Ochiya,et al.  Development of miRNA‐based therapeutic approaches for cancer patients , 2019, Cancer science.

[6]  Yanyan Jiang,et al.  MiR-187-3p Enhances Propranolol Sensitivity of Hemangioma Stem Cells. , 2019, Cell structure and function.

[7]  Kunmei Liu,et al.  Characterization of microRNA expression profiles by deep sequencing of small RNA libraries in leukemia patients from Naxi ethnic , 2019, Translational cancer research.

[8]  Ying-bin Liu,et al.  MicroRNA‑424 suppresses the proliferation of hemangioma‑derived endothelial cells by targeting VEGFR‑2. , 2018, Molecular medicine reports.

[9]  J. Szemraj,et al.  Single‐nucleotide polymorphisms of VEGF‐A and VEGFR‐2 genes and risk of infantile hemangioma , 2018, International journal of dermatology.

[10]  Guan-feng Yu,et al.  Co-suppression of VEGF-A and VEGF-C inhibits development of experimental hemangioma. , 2018, American journal of translational research.

[11]  Qiurong Ruan,et al.  The expression and function of miR-424 in infantile skin hemangioma and its mechanism , 2017, Scientific Reports.

[12]  Yuqiang Li,et al.  Mechanisms of Action of MicroRNAs in Infantile Hemangioma Tissue and Vascular Endothelial Cells in Different Periods , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[13]  Christine Léauté-Labrèze,et al.  Infantile haemangioma , 2017, The Lancet.

[14]  I. Papangeli,et al.  A PPARγ-dependent miR-424/503-CD40 axis regulates inflammation mediated angiogenesis , 2017, Scientific Reports.

[15]  Zhang Yu,et al.  When to stop propranolol for infantile hemangioma , 2017, Scientific Reports.

[16]  F. Gao,et al.  Epigenetic silencing of miR-130a ameliorates hemangioma by targeting tissue factor pathway inhibitor 2 through FAK/PI3K/Rac1/mdm2 signaling. , 2017, International journal of oncology.

[17]  W. Mackey Infantile Hemangioma with a Focus on Airway Hemangioma. , 2016, ORL-head and neck nursing : official journal of the Society of Otorhinolaryngology and Head-Neck Nurses.

[18]  P. Li,et al.  Propranolol induces regression of hemangioma cells via the down‐regulation of the PI3K/Akt/eNOS/VEGF pathway , 2015, Pediatric blood & cancer.

[19]  P. Li,et al.  Propranolol represses infantile hemangioma cell growth through the β2-adrenergic receptor in a HIF-1α-dependent manner. , 2015, Oncology reports.

[20]  W. Liu,et al.  Role of miR-424 on angiogenic potential in human dental pulp cells. , 2014, Journal of endodontics.

[21]  Quan Xu,et al.  [Establishment of human infancy hemangioma-derived endothelial cell line XPTS-1 and animal model of human infancy hemangioma]. , 2011, Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology.

[22]  E. Boscolo,et al.  Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression , 2010, Angiogenesis.

[23]  E. Boscolo,et al.  Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. , 2010, The New England journal of medicine.